Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

439 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort.
Torti C, Maggiolo F, Patroni A, Suter F, Ladisa N, Paraninfo G, Pierotti P, Orani AM, Minoli L, Arici C, Sighinolfi L, Tinelli C, Carosi G; MASTER Cohort. Torti C, et al. Among authors: tinelli c. J Antimicrob Chemother. 2005 Jul;56(1):190-5. doi: 10.1093/jac/dki172. Epub 2005 May 25. J Antimicrob Chemother. 2005. PMID: 15917286
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
Torti C, Lapadula G, Casari S, Puoti M, Nelson M, Quiros-Roldan E, Bella D, Pastore G, Ladisa N, Minoli L, Sotgiu G, Mazzotta F, Lo Caputo S, Di Perri G, Filice G, Tinelli C, Carosi G; EPOKA-MASTER Study Group. Torti C, et al. Among authors: tinelli c. BMC Infect Dis. 2005 Jul 14;5:58. doi: 10.1186/1471-2334-5-58. BMC Infect Dis. 2005. PMID: 16018804 Free PMC article.
Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switch.
Tomasoni LR, Patroni A, Torti C, Paraninfo G, Gargiulo F, Quiros-Roldan E, Uccelli MC, Airò P, Tinelli C, Carosi G, Castelli F; Brescia-MASTER Study Group. Tomasoni LR, et al. Among authors: tinelli c. HIV Clin Trials. 2003 Sep-Oct;4(5):311-23. doi: 10.1310/FGMF-Y0LY-DMX8-371V. HIV Clin Trials. 2003. PMID: 14583847
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial.
Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, Lazzarin A, Angarano G, Maserati R, Gianotti N, Ladisa N, Quiros-Roldan E, Rinehart AR, Carosi G; Genotipo-Fenotipo di Resistenza (GenPheRex) Group of the Italian Management Standardizzato di Terapia Antiretrovirale (MASTER) Cohort. Mazzotta F, et al. Among authors: tinelli c. J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):268-80. doi: 10.1097/00126334-200303010-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12626886 Clinical Trial.
Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients.
Torti C, Quiros-Roldan E, Keulen W, Scudeller L, Lo Caputo S, Boucher C, Castelli F, Mazzotta F, Pierotti P, Been-Tiktak AM, Buccoliero G, De Gennaro M, Carosi G, Tinelli C; GenPherex Study Group of the MaSTeR Cohort. Torti C, et al. Among authors: tinelli c. J Infect Dis. 2003 Jul 15;188(2):194-201. doi: 10.1086/376512. Epub 2003 Jul 1. J Infect Dis. 2003. PMID: 12854073
439 results